UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 24, 2007

Neurocrine Biosciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)		0-22705 (Commission File Number)		33-0525145 (I.R.S. Employer Identification No.)

12790 El Camino Real San Diego, California		92130
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (858) 617-7600

Not Applicable.
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

o		Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o		Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o		Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o		Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

Item 5.02.		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(e) On October 24, 2007, we entered into Stock Option Cancellation Agreements with certain of our executive officers and directors, pursuant to which certain stock options previously granted to each such executive officer or director were cancelled in exchange for a nominal payment by us of $100 in the aggregate.

     The Stock Option Cancellation Agreements indicated that other than such nominal payment, the applicable executive officer or director had not received, and would not receive, any additional consideration in exchange for the cancellation of such options. Accordingly, while each such executive officer or director will be eligible to receive future equity grants in connection with our regular grant practices, no such executive officer or director will receive any future equity award in exchange for the cancellation of such options.

     The executive officers and directors that entered into Stock Option Cancellation Agreements, and the aggregate number of shares underlying the stock options cancelled pursuant to such agreements, are as follows:

				Aggregate
				Number of
				Shares
				Underlying
Name		Title		Stock Options
Joseph A. Mollica, Ph.D.		Chairman of the Board			15,000
Corinne H. Lyle		Director			20,000
W. Thomas Mitchell		Director			12,000
Richard F. Pops		Director			12,000
Wylie W. Vale, Ph.D.		Director			12,000
Stephen A. Sherwin, M.D.		Director			12,000
Gary A. Lyons		President, Chief Executive Officer and Director			80,000
Margaret Valeur-Jensen, J.D., Ph.D.		Executive Vice President, General Counsel and Corporate Secretary			23,500
Kevin C. Gorman, Ph.D.		Executive Vice President and Chief Operating Officer			52,000
Richard Ranieri		Senior Vice President, Human Resources			6,000

     A copy of the form of Stock Option Cancellation Agreement is attached as Exhibit 10.1 hereto and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Number		Description
10.1		Form of Stock Option Cancellation Agreement

SIGNATURE

     Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 26, 2007

EXHIBIT INDEX

Number		Description
10.1		Form of Stock Option Cancellation Agreement